Dear Editor, I want to congratulate Yoo and colleagues for their article [1] in which they developed and validated a predictive model to identify long-term survivors among metastatic breast cancer patients who had undergone primary tumor surgery. Among these patients, advanced T-stage, highgrade tumor, lymphovascular invasion, negative estrogen receptor status, high Ki-67 expression, and abnormal CA 15-3 and alkaline phosphatase levels were associated with poor survival. However, the authors did not mention frequency of patients who received loco-regional radiotherapy (RT) which may affect survival of these patients. As associated with this, medical records of 227 patients with de novo stage IV breast cancer between April 1999 and January 2013 were retrospectively evaluated in our study [2] . In our study population, 188 (82.8%) patients had locoregional treatment (LRT) [2 (1%) had loco-regional RT alone, 54 (29%) had surgery alone (mastectomy, n = 50; breast-conserving surgery (BCS), n = 4), and 132 (70%) had surgery (mastectomy, n = 119; BCS, n = 13) followed by loco-regional RT]. The median follow-up time was 35 months (range 4-149 months). The 5-year OS and PFS rates were significantly higher in patients treated with loco-regional RT than the ones who were not. In conclusion, our study results supported that addition of locoregional RT increases the survival of metastatic breast cancer patients who had undergone primary tumor surgery. Therefore, loco-regional RT might be considered as an important independent variable to predict survival.
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